The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
Open accessAbstract
Both genome-wide genetic and epigenetic alterations are fundamentally important for the development of cancers, but the interdependence of these aberrations is poorly understood. Glioblastomas and other cancers with the CpG island methylator phenotype (CIMP) constitute a subset of tumours with extensive epigenomic aberrations and a distinct biology. Glioma CIMP (G-CIMP) is a powerful determinant of tumour pathogenicity, but the molecular basis of G-CIMP remains unresolved. Here we show that mutation of a single gene, isocitrate dehydrogenase 1 (IDH1), establishes G-CIMP by remodelling the methylome. This remodelling results in reorganization of the methylome and transcriptome. Examination of the epigenome of a large set of intermediate-grade gliomas demonstrates a distinct G-CIMP phenotype that is highly dependent on the presence of IDH mutation. Introduction of mutant IDH1 into primary human astrocytes alters specific histone marks, induces extensive DNA hypermethylation, and reshapes the methylome in a fashion that mirrors the changes observed in G-CIMP-positive lower-grade gliomas. Furthermore, the epigenomic alterations resulting from mutant IDH1 activate key gene expression programs, characterize G-CIMP-positive proneural glioblastomas but not other glioblastomas, and are predictive of improved survival. Our findings demonstrate that IDH mutation is the molecular basis of CIMP in gliomas, provide a framework for understanding oncogenesis in these gliomas, and highlight the interplay between genomic and epigenomic changes in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“IDH mutant gliomas thus manifest a CpG island methylator phenotype (G-CIMP)10,11, though the functional significance of this altered epigenetic state remains unclear.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [11]
In the citing paper
“As a result, D-2HG accumulation in cancer cells expressing mutant IDH results in hypermethylation of histones and CpG islands in DNA (Figueroa et al., 2010; Lu et al., 2012; Turcan et al., 2012).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Turcan et al., 2012
In the citing paper
“Specifically, owing to the interference with TET family proteins, the mutation causes the CpG island methylator phenotype116,123.”
From Transcription factors as readers and effectors of DNA methylation (2016) · cites this paper as [123]
In the citing paper
“Indeed, IDH-driven gliomas, leukemias and chondrosarcomas display a prominent CpG island hypermethylation, reminiscent of the hypermethylator phenotype seen in SDH- and FH-deficient cancers (Figueroa et al., 2010; Lu et al., 2013; Turcan et al., 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Turcan et al., 2012
In the citing paper
“In the cancer setting, 2-HG has been shown to influence a number of biological processes, including cell differentiation, DNA methylation, and histone methylation (79–82), leading to its classification as an oncometabolite.”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [82]
In the citing paper
“Like TH17 cells, CD8+ T cells are highly dependent on the activation of HIF-1α and glycolysis, which is responsible for mediating trafficking into hypoxic tumour environments and inflamed tissue147,148.”
From Coupling Krebs cycle metabolites to signalling in immunity and cancer (2018) · cites this paper as [147]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.12.020 · Cited by 7,575
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
An Integrated Genomic Analysis of Human Glioblastoma Multiforme
Parsons, D. W., Jones, S., Zhang, X., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I.-M., Gallia, G. L., et al. (2008) · Science · doi:10.1126/science.1164382 · Cited by 5,857
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationConsed: a graphical tool for sequence finishing.Preprint
Gordon, D., Abajian, C., & Green, P. (1998) · Genome Research · doi:10.1101/gr.8.3.195 · Cited by 3,706
CNS stem cells express a new class of intermediate filament protein
Lendahl, U., Zimmerman, L. B., & McKay, R. D. G. (1990) · Cell · doi:10.1016/0092-8674(90)90662-x · Cited by 3,164
Cited by
Sorted by citations
Items 701–800 of 1,002
Tissue and Cell-Free DNA-Based Epigenomic Approaches for Cancer Detection
Leal, A., Sidransky, D., & Brait, M. (2019) · Clinical Chemistry · doi:10.1373/clinchem.2019.303594 · Cited by 42
Du, J., Yan, X., Mi, S., Yuan, L., Ji, H., Hou, K., Ma, S., Ba, Y., Zhou, P., Chen, L., et al. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.558961 · Cited by 40
Wirsching, H., & Weller, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-49864-5_18 · Cited by 43
Identification of novel prognostic targets in glioblastoma using bioinformatics analysis
Yin, X., Wu, Q., Hao, Z., & Chen, L. (2022) · BioMedical Engineering OnLine · doi:10.1186/s12938-022-00995-8 · Cited by 40
Vilar, J. B., Christmann, M., & Tomicic, M. T. (2022) · Cancers · doi:10.3390/cancers14102416 · Cited by 43
The Interplay between T Cells and Cancer: The Basis of Immunotherapy
Chen, C., Liu, X., Chang, C., Wang, H. Y., & Wang, R. (2023) · Genes · doi:10.3390/genes14051008 · Cited by 42
Oncogenic Viruses and the Epigenome: How Viruses Hijack Epigenetic Mechanisms to Drive Cancer
MacLennan, S., & Marra, M. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119543 · Cited by 42
Epigenetic dysregulation: a novel pathway of oncogenesis in pediatric brain tumors
Fontebasso, A. M., Gayden, T., Nikbakht, H., Neirinck, M., Papillon‐Cavanagh, S., Majewski, J., & Jabado, N. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1325-8 · Cited by 40
Epigenetic profiling joins personalized cancer medicine
Heyn, H., Méndez‐González, J., & Esteller, M. (2013) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.13.36 · Cited by 39
DNA methylation subgroups in melanoma are associated with proliferative and immunological processes
Lauss, M., Ringnér, M., Karlsson, A., Harbst, K., Busch, C., Geisler, J., Lønning, P. E., Staaf, J., & Jönsson, G. B. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0147-4 · Cited by 40
The Role of Molecular Diagnostics in the Management of Patients with Gliomas
Wirsching, H., & Weller, M. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0430-4 · Cited by 39
Yang, D., Jiang, H., Lu, J., Lv, Y., Baiyun, R., Li, S., Liu, B., Lv, Z., & Zhang, Z. (2018) · Environmental Pollution · doi:10.1016/j.envpol.2018.02.035 · Cited by 39
CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo
Meng, W., Wang, J., Wang, B., Liu, F., Li, M. C., Yang, Z., Zhang, C., Li, Q., Chen, J., Zhang, L., et al. (2018) · Cancer Management and Research · doi:10.2147/cmar.s183696 · Cited by 39
HNF4α pathway mapping identifies wild-type IDH1 as a targetable metabolic node in gastric cancer
Xu, C., Ooi, W. F., Qamra, A., Tan, J. Y., Chua, B. Y.-J., Ho, S. W. T., Das, K., Isa, Z. F. A., Li, Z., Yao, X., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-318025 · Cited by 40
The EGFR-ZNF263 signaling axis silences SIX3 in glioblastoma epigenetically
Yu, Z., Feng, J., Wang, W., Deng, Z., Zhang, Y., Xiao, L., Wang, Z., Liu, C., Liu, Q., Chen, S., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1206-7 · Cited by 39
Molecular markers and targeted therapy in pediatric low-grade glioma
de Blank, P. M. K., Fouladi, M., & Huse, J. T. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03529-1 · Cited by 41
Self-citationMitochondrial Control of Genomic Instability in Cancer
Bonora, M., Missiroli, S., Perrone, M., Fiorica, F., Pinton, P., & Giorgi, C. (2021) · Cancers · doi:10.3390/cancers13081914 · Cited by 42
Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2
Lv, D., Dixit, D., Cruz, A. F., Kim, L. J. Y., Duan, L., Xu, X. Y., Wu, Q., Zhong, C., Lu, C., Gersey, Z. C., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.014 · Cited by 47
Self-citationMetabolism–epigenome crosstalk in physiology and diseases
Hino, S., Nagaoka, K., & Nakao, M. (2013) · Journal of Human Genetics · doi:10.1038/jhg.2013.57 · Cited by 39
IDH1, lipid metabolism and cancer: Shedding new light on old ideas
Bogdanovic, E. (2015) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2015.04.014 · Cited by 39
G-Cimp Status Prediction Of Glioblastoma Samples Using mRNA Expression Data
Baysan, M. S., Bozdag, S., Cam, M. C., Kotliarova, S. E., Ahn, S. J., Walling, J., Killian, J. K., Stevenson, H. S., Meltzer, P. S., & Fine, H. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047839 · Cited by 38
Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis
Ohba, S., & Hirose, Y. (2016) · Neurologia medico-chirurgica · doi:10.2176/nmc.ra.2015-0322 · Cited by 38
Doll, S., Urisman, A., Osés-Prieto, J. A., Arnott, D. P., & Burlingame, A. L. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m116.063883 · Cited by 39
Bhargava, S., Patil, V. S., Mahalingam, K., & Somasundaram, K. (2016) · Oncotarget · doi:10.18632/oncotarget.14287 · Cited by 38
Chen, C., Shi, Y., Li, Y., He, Z., Zhou, K., Zhang, X., Yang, K., Wu, J.-R., Kung, H., Ping, Y., et al. (2017) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2017.05.007 · Cited by 38
Pisapia, D. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0493-ra · Cited by 43
Wei, S., Wang, J., Oyinlade, O., Ma, D., Wang, S., Kratz, L. E., Lal, B., Xu, Q., Liu, S., Shah, S. R., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0334-9 · Cited by 37
Teng, Y. D., Abd‐El‐Barr, M. M., Wang, L., Hajiali, H., Wu, L., & ZAFONTE, R. D. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.09.010 · Cited by 37
Transcriptional and epigenetic mechanisms underlying astrocyte identity
Pavlou, M. A. S., Grandbarbe, L., Buckley, N. J., Niclou, S. P., & Michelucci, A. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.12.007 · Cited by 37
Detection of statistically significant network changes in complex biological networks
Mall, R., Cerulo, L., Bensmail, H., Iavarone, A., & Ceccarelli, M. (2017) · BMC Systems Biology · doi:10.1186/s12918-017-0412-6 · Cited by 38
Effects of 1p/19q Codeletion on Immune Phenotype in Low Grade Glioma
Lv, L., Zhang, Y., Zhao, Y., Wei, Q., Zhao, Y., & Yi, Q. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.704344 · Cited by 38
The mechanisms of IDH mutations in tumorigenesis
Ye, D., Xiong, Y., & Guan, K. (2012) · Cell Research · doi:10.1038/cr.2012.51 · Cited by 38
Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
Viswanath, P., Chaumeil, M. M., & Ronen, S. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00060 · Cited by 38
Oizel, K., Gratas, C., Nadaradjane, A., Oliver, L., Vallette, F. M., & Pecqueur, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.13 · Cited by 38
Epigenetic alterations in cancer and personalized cancer treatment
Miozzo, M. R., Vaira, V., & Sirchia, S. M. (2015) · Future Oncology · doi:10.2217/fon.14.237 · Cited by 37
Jafari‐Khouzani, K., Loebel, F., Bogner, W., Rapalino, O., González, R. G., Gerstner, E. R., Chi, A. S., Batchelor, T. T., Rosen, B. R., Unkelbach, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now100 · Cited by 37
Jungk, C., Möck, A., Exner, J., Geisenberger, C., Warta, R., Capper, D., Abdollahi, A., Friauf, S., Lahrmann, B., Grabe, N., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0710-7 · Cited by 38
IGFBP2 expression predicts IDH-mutant glioma patient survival
Huang, L. E., Cohen, A. L., Colman, H., Jensen, R. L., Fults, D. W., & Couldwell, W. T. (2016) · Oncotarget · doi:10.18632/oncotarget.13329 · Cited by 37
Neurological update: gliomas and other primary brain tumours in adults
Brandner, S., & Jaunmuktane, Z. (2017) · Journal of Neurology · doi:10.1007/s00415-017-8652-3 · Cited by 38
Baulch, J. E. (2018) · International Journal of Radiation Biology · doi:10.1080/09553002.2018.1549757 · Cited by 37
Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas
Filipski, K., Braun, Y., Zinke, J., Roller, B., Baumgarten, P., Wagner, M., Senft, C., Zeiner, P. S., Ronellenfitsch, M. W., Steinbach, J. P., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02025-9 · Cited by 36
Dekker, L. J. M., Wu, S., Jurriëns, C., Mustafa, D. A. M., Grevers, F., Burgers, P. C., Smitt, P. A. E. S., Kros, J. M., & Luider, T. M. (2020) · The FASEB Journal · doi:10.1096/fj.201902352r · Cited by 39
Targeting the Ubiquitin System in Glioblastoma
Scholz, N., Kurian, K. M., Siebzehnrübl, F. A., & Licchesi, J. D. F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574011 · Cited by 37
From Laboratory Studies to Clinical Trials: Temozolomide Use in IDH-Mutant Gliomas
Sun, X., & Turcan, Ş. (2021) · Cells · doi:10.3390/cells10051225 · Cited by 38
Yoon, J., Grinchuk, O. V., Tirado-Magallanes, R., Ngian, Z., Tay, E. X. Y., Chuah, Y. H., Lee, B. W. L., Jia, F., Crasta, K., Ong, C., et al. (2022) · Cell Death and Differentiation · doi:10.1038/s41418-021-00926-5 · Cited by 39
Comparative transcriptomics reveals similarities and differences between astrocytoma grades
Seifert, M., Garbe, M., Friedrich, B., Mittelbronn, M. G. A., & Klink, B. (2015) · BMC Cancer · doi:10.1186/s12885-015-1939-9 · Cited by 38
Current therapeutic approaches to diffuse grade II and III gliomas
Pïcca, A., Berzero, G., & Sanson, M. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285617752039 · Cited by 39
Explainable artificial intelligence of DNA methylation-based brain tumor diagnostics
Benfatto, S., Sill, M., Jones, D., Pfister, S. M., Sahm, F., von Deimling, A., Capper, D., & Hovestadt, V. (2025) · Nature Communications · doi:10.1038/s41467-025-57078-0 · Cited by 39
Peroxisome biogenesis in mammalian cells: The impact of genes and environment
Farr, R. L., Lismont, C., Terlecky, S. R., & Fransen, M. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.08.011 · Cited by 37
Mitochondrial energy metabolism and apoptosis regulation in glioblastoma
Nagy, Á., Éder, K., Selak, M. A., & Kálmán, B. (2014) · Brain Research · doi:10.1016/j.brainres.2014.10.062 · Cited by 37
Genomics of Brain Tumor Imaging
Pope, W. B. (2014) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2014.09.006 · Cited by 37
New Strategies in Glioblastoma: Exploiting the New Biology
Fine, H. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1328 · Cited by 35
Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
Viswanath, P., Najac, C., Izquierdo-García, J. L., Pankov, A., Hong, C., Eriksson, P., Costello, J., Pieper, R. O., & Ronen, S. M. (2016) · Oncotarget · doi:10.18632/oncotarget.9006 · Cited by 35
Brain Tumors: Epidemiology and Current Trends in Treatment
Strong, M. J., & Garces, J. (2016) · Journal of Brain Tumors & Neurooncology · doi:10.4172/2475-3203.1000102 · Cited by 44
Molecular pathogenesis and therapeutic implications in pediatric high-grade gliomas
Juratli, T. A., Qin, N., Cahill, D. P., & Filbin, M. G. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.08.006 · Cited by 36
Transcriptional regulators and alterations that drive melanoma initiation and progression
Gupta, R., Janoštiak, R., & Wajapeyee, N. (2020) · Oncogene · doi:10.1038/s41388-020-01490-x · Cited by 36
Schwarzenbach, C., Tatsch, L., Vilar, J. B., Rasenberger, B., Beltzig, L., Kaina, B., Tomicic, M. T., & Christmann, M. (2021) · Cancers · doi:10.3390/cancers13143585 · Cited by 39
Evolving Treatment Strategies for Elderly Leukemia Patients with IDH Mutations
Buege, M. J., DiPippo, A. J., & Dinardo, C. D. (2018) · Cancers · doi:10.3390/cancers10060187 · Cited by 35
The Role of Thymine DNA Glycosylase in Transcription, Active DNA Demethylation, and Cancer
Onabote, O., Hassan, H. M., Isovic, M., & Torchia, J. (2022) · Cancers · doi:10.3390/cancers14030765 · Cited by 38
The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancer
Liu, Y., Xu, W., Li, M., Yang, Y., Sun, D., Chen, L., Li, H., & Chen, L. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.12.019 · Cited by 37
TCA cycle-derived oncometabolites in cancer and the immune microenvironment
Sarkar, S., Chang, C.-I., Jean, J., & Wu, M. (2025) · Journal of Biomedical Science · doi:10.1186/s12929-025-01186-y · Cited by 39
Jha, P., Patric, I. R. P., Shukla, S. K., Pathak, P., Pal, J., Sharma, V., Thinagararanjan, S., Santosh, V., Suri, V. S., Sharma, M. C., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou113 · Cited by 35
Biodegradable micelles enhance the antiglioma activity of curcumin in vitro and in vivo
Gao, X. X., Zheng, S., Yu, T., Zheng, T., Liu, X., Wang, Y., & You, C. (2016) · International Journal of Nanomedicine · doi:10.2147/ijn.s102450 · Cited by 35
Andersen, G. B., & Tost, J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7481-8_1 · Cited by 36
Impact of Multifocality and Molecular Markers on Survival of Glioblastoma
Ahmadipour, Y., Jabbarli, R., Gembruch, O., Pierscianek, D., Oppong, M. D., Dammann, P. R., Wrede, K. H., Özkan, N., Müller, O., Sure, U., et al. (2018) · World Neurosurgery · doi:10.1016/j.wneu.2018.10.075 · Cited by 35
TERT and DNMT1 expression predict sensitivity to decitabine in gliomas
Park, J., Sahm, F., Steffl, B., Arrillaga‐Romany, I., Cahill, D. P., Monje, M., Herold‐Mende, C. C., Wick, W., & Turcan, Ş. (2020) · Neuro-Oncology · doi:10.1093/neuonc/noaa207 · Cited by 35
Therapy for advanced cholangiocarcinoma: Current knowledge and future potential
Wang, M., Chen, Z., Guo, P., Wang, Y., & Chen, G. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16151 · Cited by 35
Weng, J., & Salazar, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031020 · Cited by 35
Harnessing Lactate Metabolism for Radiosensitization
Liu, K. X., Everdell, E., Pal, S., Haas-Kogan, D. A., & Milligan, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672339 · Cited by 36
Lyu, C., Niu, Y., Lai, W., Wang, Y., Wang, Y., Dai, P., Ma, C., Chen, S., Li, Y., Jiang, G., et al. (2022) · Cell Discovery · doi:10.1038/s41421-022-00399-x · Cited by 35
Mala, U., Baral, T. K., & Somasundaram, K. (2022) · BMC Cancer · doi:10.1186/s12885-022-09682-2 · Cited by 35
Molecular subtypes of glioma identified by genome‐wide methylation profiling
Kloosterhof, N. K., de Rooi, J. J., Kros, M., Eilers, P. H. C., Smitt, P. A. E. S., van den Bent, M. J., & French, P. J. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22062 · Cited by 35
Yao, Y., Chan, A. K., Qin, Z., Chen, L. C., Zhang, X., Pang, J. C., Li, H. M., Wang, Y., Mao, Y. Q., Ng, H., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0067421 · Cited by 34
Predictive biomarkers in adult gliomas
Thomas, L., Stefano, A. L. D., & Ducray, F. (2013) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000002 · Cited by 34
Incorporation of Prognostic and Predictive Factors Into Glioma Clinical Trials
Johnson, D. R., & Galanis, E. (2012) · Current Oncology Reports · doi:10.1007/s11912-012-0279-z · Cited by 34
Tumor-Suppressive miR148a Is Silenced by CpG Island Hypermethylation in IDH1 -Mutant Gliomas
Li, S., Chowdhury, R., Liu, F., Chou, A. P., Li, T., Mody, R. R., Lou, J. J., Chen, W., Reiss, J., Soto, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0234 · Cited by 34
Gladitz, J., Klink, B., & Seifert, M. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0544-y · Cited by 33
Cao, J., Guo, Q., Guan, G., Zhu, C., Zou, C., Zhang, L., Cheng, W., Wang, G., Cheng, P., Wu, A., et al. (2020) · Aging · doi:10.18632/aging.102706 · Cited by 34
Wong, D., & Yip, S. S. F. (2020) · The Journal of Pathology · doi:10.1002/path.5400 · Cited by 36
Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas
Martins, F., Gonçalves, L. G., Pojo, M., & Serpa, J. (2020) · Biomolecules · doi:10.3390/biom10101370 · Cited by 35
Ke, X. X., Zhang, R., Zhong, X. Z., Zhang, L., & Cui, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.593964 · Cited by 34
Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression
Ntziachristos, P., Mullenders, J., Trimarchi, T., & Aifantis, I. (2013) · Advances in immunology · doi:10.1016/b978-0-12-410524-9.00001-3 · Cited by 37
Wang, P., Lv, C., & Zhu, G. (2015) · Scientific Reports · doi:10.1038/srep09150 · Cited by 35
Current and Investigational Drug Strategies for Glioblastoma
Ajaz, M., Jefferies, S., Brazil, L., Watts, C., & Chalmers, A. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.012 · Cited by 35
Warburg and Krebs and related effects in cancer
Unterlass, J. E., & Curtin, N. J. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.4 · Cited by 35
Jiang, B., Zhang, J., Xia, J., Zhao, W., Wu, Y., Shi, M., Luo, L., Zhou, H., Chen, A., Ma, H., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.053 · Cited by 33
Stalled oligodendrocyte differentiation in IDH-mutant gliomas
Wei, Y., Li, G., Feng, J. H., Wu, F., Zhao, Z., Bao, Z., Zhang, W., Su, X., Li, J., Qi, X., et al. (2023) · Genome Medicine · doi:10.1186/s13073-023-01175-6 · Cited by 36
Meng, D., Chen, Y., Yun, D., Zhao, Y., Wang, J., Xu, T., Li, X., Wang, Y., Li, Y., Sun, R., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3208 · Cited by 34
Michaelsen, S. R., Urup, T. H., Olsen, L. R., Broholm, H., Lassen, U., & Poulsen, H. S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-017-2739-7 · Cited by 35
Pangeni, R. P., Zhang, Z., Alvarez, A. A., Wan, X., Sastry, N. G., Lu, S., Shi, T., Huang, T., Lei, C. X., James, C. D., et al. (2018) · Epigenetics · doi:10.1080/15592294.2018.1469892 · Cited by 33
Fazi, B., Proserpio, C., Galardi, S., Annesi, F., Cola, M., Mangiola, A., Michienzi, A., & Ciafrè, S. A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102496 · Cited by 33
Methylation‐based algorithms for diagnosis: experience from neuro‐oncology
Pickles, J. C., Stone, T. J., & Jacques, T. S. (2020) · The Journal of Pathology · doi:10.1002/path.5397 · Cited by 33
Macklin, P. S., Yamamoto, A., Browning, L., Hofer, M., Adam, J., & Pugh, C. W. (2020) · The Journal of Pathology · doi:10.1002/path.5402 · Cited by 33
Qi, C., Lei, L., Hu, J., Wang, G., Liu, J., & Ou, S. (2020) · Oncology Letters · doi:10.3892/ol.2020.12283 · Cited by 33
Castro, L. N. G., Liu, I., & Filbin, M. G. (2022) · Neuro-Oncology · doi:10.1093/neuonc/noac211 · Cited by 34
Role of N6-methyladenosine methylation in glioma: recent insights and future directions
Li, C., Li, B., Wang, H., Qu, L., Liu, H., Weng, C., Han, J., & Li, Y. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00514-0 · Cited by 36
Deregulated proliferation and differentiation in brain tumors
Swartling, F. J., Čančer, M., Frantz, A., Weishaupt, H., & Persson, A. I. (2014) · Cell and Tissue Research · doi:10.1007/s00441-014-2046-y · Cited by 32
Popov, S., Jury, A., Laxton, R. C., Doey, L. J., Kandasamy, N., Al‐Sarraj, S., Jürgensmeier, J. M., & Jones, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056328 · Cited by 33
Li, A. M., & Ye, J. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062822-120857 · Cited by 31
The hidden architects of glioblastoma multiforme: Glioma stem cells
Sahoo, O. S., Mitra, R., & Nagaiah, N. K. H. (2024) · MedComm – Oncology · doi:10.1002/mog2.66 · Cited by 33
Metadata
- Authors
- Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E., Campos, C., Fabius, A. W. M., Lu, C., Ward, P. S., Thompson, C. B., Kaufman, A., Guryanova, O., Levine, R., Heguy, A., Viale, A., Morris, L. G. T., Huse, J. T., Mellinghoff, I. K., & Chan, T. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Mellinghoff, Ingo K.
- Chan, Timothy A.
- ORCID
- Venue
- Nature
- Published
- 2012-02-15
- Volume
- 483
- Issue
- 7390
- Pages
- 479-483
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3351699
- OpenAlex
- W1988756388
- Cited by
- 1,974
- References
- 44
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 100 · 2022: 136 · 2021: 148 · 2020: 140 · 2019: 142 · 2018: 169 · 2017: 144 · 2016: 163 · 2015: 154 · 2014: 153 · 2013: 152 · 2012: 83
- FWCI
- 82.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Cancer Institute (F31CA260794, R01CA154767, U54CA143798, P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, glioma, CpG island methylator phenotype, DNA hypermethylation, 2-hydroxyglutarate, oncometabolites, histone demethylation, methylome, astrocytes, gliomagenesis, hypoxia-inducible factor, epigenetic reprogramming
- MeSH terms
- Astrocytes, Cell Survival, Cells, Cultured, Gene Expression Regulation, Glioblastoma, Glioma, Histones, Humans, Isocitrate Dehydrogenase, Mutation, Phenotype, Tumor Cells, Cultured, CpG Islands, DNA Methylation, Epigenesis, Genetic, Metabolome, HEK293 Cells, Epigenomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
